The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation
- PMID: 36697133
- DOI: 10.1016/j.jacc.2022.11.024
The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation
Keywords: ACEI; ARB; angioedema; real-world; sacubitril-valsartan.
Conflict of interest statement
Funding Support and Author Disclosures The author has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.J Am Coll Cardiol. 2023 Jan 31;81(4):321-331. doi: 10.1016/j.jacc.2022.10.033. J Am Coll Cardiol. 2023. PMID: 36697132
Similar articles
-
Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.ESC Heart Fail. 2022 Feb;9(1):667-675. doi: 10.1002/ehf2.13691. Epub 2021 Nov 14. ESC Heart Fail. 2022. PMID: 34779134 Free PMC article.
-
Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.Am Heart J. 2022 Aug;250:23-28. doi: 10.1016/j.ahj.2022.04.007. Epub 2022 May 4. Am Heart J. 2022. PMID: 35525261
-
Impact of Sacubitril/Valsartan on Right Heart Failure.Int Heart J. 2021 Jul 30;62(4):932-934. doi: 10.1536/ihj.21-111. Epub 2021 Jul 17. Int Heart J. 2021. PMID: 34276024
-
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Circulation. 2016. PMID: 26976916 Free PMC article. Review.
-
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.J Cardiovasc Pharmacol. 2021 Aug 1;78(2):202-210. doi: 10.1097/FJC.0000000000001049. J Cardiovasc Pharmacol. 2021. PMID: 33929386
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical